Angel Matthew purchased $500K of TPST (indirect holdings)
Angel Matthew (CEO and President) purchased 231,482 indirectly-held shares of Tempest Therapeutics, Inc. (TPST) at $2.16 ($0.50M total) on 2026-03-24.
How this was made
The 30-second read
Why it matters
The newest fact is the reported open-market purchase by the CEO/President, which can modestly influence sentiment but does not change fundamentals on its own.
Market read
Traders may treat this as a mild bullish sentiment datapoint, but it is unlikely to drive a major repricing without accompanying operational news.
What to watch
No 10b5-1 plan is stated, but the transaction date (2026-03-24) is earlier than the filing date, reducing immediacy for price discovery.
Background
The article is an SEC Form 4 insider transaction disclosure for Tempest Therapeutics, Inc.
Ticker impact
Tempest Therapeutics CEO/President Angel Matthew filed an open-market purchase of 231,482 shares (~$500k) on 2026-03-24 via Form 4.
Likely limited/short-lived price reaction; more relevant for sentiment than fundamentals.
The filing is a primary Form 4 disclosure with a specific buy transaction, yet it is not a new operating catalyst and is described as indirect holdings with no 10b5-1 plan.
Market effects
No clear sector read-through; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
Indirect holdings and a single ~$500k buy may reflect routine liquidity/compensation mechanics rather than a strong forward view.
Key entities
- issuerTempest Therapeutics, Inc.
TPST; subject of the Form 4 insider transaction disclosure.
- insiderAngel Matthew
CEO and President; reported open-market purchase of 231,482 shares (~$500,001.12) via indirect holdings.
